“Is the generic version of Arixtra as safe and effective as brand Arixtra?” Answer: “Yes”.
The FDA evaluated and approved generic fondaparinux made by Dr. Reddy’s Laboratories Ltd. on July 11, 2011 (announcement about approval here). Fondaparinux (Arixtra) is a once daily s.c. anticoagulant and can be given
- for DVT prevention at a lower, i.e. prophylactic, dose, or
- for treatment of DVT and PE at a higher, i.e;. at full therapeutic dose overlapping with warfarin in the first few days of warfarin initiation, or
- as an alternative to warfarin in patients who have had recurrent VTE in spite of adequate INRs on warfarin (i.e. in patients in whom warfarin has failed).
Disclosure: I have no conflict of interest relevant to this post.
Last updated: Sept 26th, 2011
Disclaimer: ClotConnect.org, its contributors, authors, advisors, members and affiliate organizations do not assume any liability for the content of the website, blog and educational materials. Medical information changes rapidly. While information is believed to be correct, no representation is made and no responsibility is assumed for the accuracy of information contained on or available through this website and blog. Information is subject to change without notice.